NovaBridge Biosciences任命Srishti Gupta为首席执行官

• NovaBridge Biosciences (NBP) appointed Srishti Gupta as CEO and a member of its board, effective July 1, succeeding Xi-Yong (Sean) Fu, who is stepping down.
• Fu will remain with the company in an advisory role during the leadership transition.
• Gupta, an experienced biopharmaceutical executive and physician, will focus on advancing the company's lead oncology candidate givastomig toward registration, expanding its ophthalmology franchise under Visara, and pursuing strategic partnerships to maximize the global potential.
• The stock price moved 2% higher on Monday pre-market trade.

More on I-Mab Biopharma

• NovaBridge's Givastomig Could Drive A Major Re-Rating
• Seeking Alpha’s Quant Rating on I-Mab Biopharma
• Historical earnings data for I-Mab Biopharma
• Financial information for I-Mab Biopharma